This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

More Hot Biotech Trades for Second Half 2011

BOSTON ( TheStreet) -- Here are some more top biotech stock trades for the second half of 2011.

The biotech stock trades listed on the following pages encompass pending FDA drug approval decisions and clinical trial results -- all of which have the potential to produce significant stock-price volatility in the next six months.

These biotech stock events/trades expected before 2011 finishes build on the list of 10 biotech stock trades that I compiled and published last week.

Represented below are an additional five pending FDA drug approvals, four phase III clinical trials and five phase II clinical trials -- all of which should occur in the second half of the year.

Targacept (TRGT - Get Report)
The event: Phase III study of TC-5214 as add-on therapy for patients with major depressive disorder.
The timelines: Top-line results from one or more of the four phase III studies expected in the fourth quarter.
The stakes: Targacept partner AstraZeneca (AZN) is conducting a large phase III study program for TC-5214 in major depressive disorder. TC-5214 is a potential blockbuster depression drug if the phase III studies are successful.

Aveo Pharmaceuticals (AVEO - Get Report)
The event: Phase III study of tivozanib in kidney cancer.
The timeline: Top-line results expected in the fourth quarter.
The stakes: Tivozanib, Aveo's lead drug, is being compared against Onyx Pharmaceuticals' (ONXX) Nexavar in first-line, advanced renal cell carcinoma, or kidney cancer. The study is designed to show that tivozanib can extend the time before tumors regrow or patients die compared to Nexavar.

Threshold Pharmaceuticals (THLD - Get Report)
The event: Phase II study of TH-302 in pancreatic cancer
The timeline: Top-line results expected in the fourth quarter.
The stakes: After a previous pancreatic cancer drug failed, Threshold is back developing another drug known as TH-302. The phase II study compares TH-302 plus the chemotherapy drug gemcitabine against gemcitabine alone in patients with first-line pancreatic cancer. The study is designed to show that the addition of TH-302 to gemcitabine can prolong the time before tumors start to grow.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ANX $0.73 0.00%
AVEO $1.92 0.00%
RPTP $10.81 0.00%
TRGT $2.43 0.00%
THLD $4.10 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs